Janssen’s subcutaneous amivantamab gains CHMP backing for EGFR-mutated lung cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of marketing authorisation for subcutaneous amivantamab treatment. This formulation of RYBREVANT (amivantamab), developed by Janssen-Cilag International NV, a Johnson & Johnson company, represents a significant step forward in the treatmen